Brii Biosciences Limited announced the appointment of Susannah Cantrell, Ph.D., as Chief Business Officer. Dr. Cantrell brings with her more than 20 years of healthcare and biotechnology industry experience spanning global pipeline strategy, sales, operations, marketing and new product commercialization. Most recently, Dr. Cantrell served as Chief Operating Officer and Chief Business Officer at Second Genome, overseeing all aspects of operations across the growing company, including R&D, finance and facilities, among other key functions.

Prior to that, she was Executive Vice President and Chief Commercial Officer at Tricida, where she established and built a high-performing U.S.-focused commercial organization. Dr. Cantrell also previously held the role of Vice President and Head of Global Commercial Strategy and Marketing Oncology at Gilead Sciences where she was instrumental in leading and growing the Company's oncology and inflammation businesses from 2011 to 2019. She also held various senior level and sales and marketing positions early on in her career at global pharmaceutical giants, Genentech/Roche and GlaxoSmithKline.

Dr. Cantrell holds a B.A. in Biology from Westminster College and a Ph.D. in Biochemistry from the University of Missouri-Columbia.